Glucagon-like peptide-1 (GLP-1) receptor agonists are widely prescribed for weight loss. Here, Hebert and colleagues discuss the need for long-term studies assessing the impacts of this on muscle mass and nutritional deficiencies, which may influence cancer susceptibility and metabolic health.
- James R. Hebert
- E. Angela Murphy
- Lorne J. Hofseth
